- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05241106
A Study of HYML-122 in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
May 13, 2024 updated by: Tarapeutics Science Inc.
a Single-arm, Open, Multicenter, Phase II Study to Investigator the Efficacy and Safety of HYML-122 in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
this is a single-arm, open, multicenter, phase 2 study to evaluate the efficacy, safety and pharmacokinetics of HYLM-122 monotherapy in Chinese subjects with FLT3 positive relapsed or refractory acute myeloid leukemia.
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
15
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yang Shu, MD. BS.
- Phone Number: 86-13918983465
- Email: shuyang@tarapeutics.com
Study Locations
-
-
Jiangsu
-
Suzhou, Jiangsu, China, 215006
- Recruiting
- The First Affiliated Hospital Of Soochow University
-
Contact:
- Depei Wu, MD. PhD
- Phone Number: 0086-0512-67781856
- Email: drwudepei@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Fully understand the procedures of the clinical study and participate voluntarily with signed and dated written informed consent form, comply with the requirements of the study protocol.
- Males and/or females at least 18 years old when signing the informed consent form.
- Histologically confirmed AML (defined using WHO criteria 2016) with one of the following:
Refractory to at least 1 cycle of induction chemotherapy. Relapsed after achieving remission with a prior therapy.
- Subject is positive for FLT3 mutation in bone marrow or blood after completion of the subject's last interventional treatment.
- Eastern cooperative oncology group performance status (ECOG) ≤2 at screening.
- Life expectancy of at least 3 months.
- Women of childbearing potential have a negative pregnancy test at baseline and are willing to employ an effective method of contraception for the entire duration of study treatment and 6 months after the last dose.
Exclusion Criteria:
- Known or suspected allergies to any of the investigational drug composition (HYML-122, lactose, hydroxypropyl cellulose, hyposubstituted hydroxypropyl cellulose, silicon dioxide, magnesium stearate, titanium dioxide and polyethylene glycol).
- Medical history and surgical history excluded according to the protocol.
- Any previous medical treatment history exclude from the protocol.
- Abnormal laboratory results exclude from the protocol.
- Combination of treatments and/or drugs required during the study period and cannot be discontinued that excluded from the protocol.
- Alcohol abuse within 6 months prior to screening, defined as long-term drinking history, generally more than 5 years, equivalent to alcohol quantity ≥40g/d for men, ≥20g/d for women, or heavy drinking history within 2 weeks, equivalent to alcohol quantity ≥80g/d. alcohol volume (g) conversion formula=alcohol consumption (mL)*alcohol content (%)*0.8.
- Abortion less than 30 days prior to screening, pregnant and lactating women (currently breast-feeding or less than one year after delivery although not breast-feeding), women of childbearing potential who are not guaranteed effective contraception during the study, planning pregnancy or donating eggs or sperm within 6 months after the last dose.
- History of drug abuse or drug addicts.
- Subjects may not be able to complete the study duo to poor compliance or other reasons, or unsuitable for the study by the investigator's judgment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HYML-122 treatment
HYML-122 tablets, 200mg spec, 28 days for each cycle.
The first eligible three enrolled subjects will be administrated with 600mg bid dose regimen for 28 consecutive days ( 1 treatment cycle).
The Data Monitoring Committee (DMC) will evaluate the safety, efficacy and PK data of these three subjects and make decision whether the regimen need to be adjusted (increasing/decreasing administration dosing or adjusting dosing frequency).
|
each treatment cycle is comprised of 28-day consecutive dosing of HYML-122.
Upon completion of each cycle, patients may continue to receive oral HYML-122 tablets if they are benefit from the treatment and the toxicity is tolerable.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ORR
Time Frame: up to 24 months
|
overall remission rate, including complete remission without minimum residual disease (CRMRD-), complete remission (CR), complete remission with incomplete hematologic recovery (CRi), complete remission without platelet recovery (CRp), partial remission (PR).
|
up to 24 months
|
composite complete remission (CRc) rate
Time Frame: up to 24 months.
|
CRc rate is defined as the rate of all complete and incomplete remission (CRMRD-+CR+CRp+CRi).
|
up to 24 months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
RFS
Time Frame: up to 24 months
|
relapse-free survival, for patients achieving a complete remission, defined as the interval from the date of first documentation of a leukemia free state to date of recurrence, treatment failure, death due to any cause or last contact of the end-of-study follow up, which ever occurs first.
|
up to 24 months
|
EFS
Time Frame: up to 24 months
|
event-free survival, EFS is defined as the time from the date of enrollment until the date of documented relapse from CR, CRp or CRi, treatment failure, death from any cause or last contact of the end-of-study follow-up, whichever occurs first.
|
up to 24 months
|
OS
Time Frame: up to 24 months
|
overall survival, OS is defined as time from the date of enrollment until the date of death from any cause.
For a subject who is not known to have died buy the end-of-study follow-up, OS is censored at the date of last contact.
|
up to 24 months
|
duration of CR remission
Time Frame: up to 24 months
|
DOR-CR is defined as the time from the date of first CR, CRp, CRi until the date of documented relapse.
|
up to 24 months
|
Incidence of Treatment-Emergent Adverse Events (Safety and tolerability)
Time Frame: up to 24 months
|
safety and tolerability of investigational product assessed as the number of participants experience adverse events (AEs, CTCAE 5.0) or abnormalities in vital signs, laboratory tests, or electrocardiograms.
|
up to 24 months
|
Cmax,ss
Time Frame: at the end of Cycle 1 (each cycle is 28 days)
|
Peak plasma concentration at steady state
|
at the end of Cycle 1 (each cycle is 28 days)
|
Cmin,ss
Time Frame: at the end of Cycle 1 (each cycle is 28 days)
|
Minimum plasma concentration at steady state
|
at the end of Cycle 1 (each cycle is 28 days)
|
Cav,ss
Time Frame: at the end of Cycle 1 (each cycle is 28 days)
|
The average steady-state plasma concentration
|
at the end of Cycle 1 (each cycle is 28 days)
|
AUCss
Time Frame: at the end of Cycle 1 (each cycle is 28 days)
|
The area under the plasma concentration at steady state
|
at the end of Cycle 1 (each cycle is 28 days)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Depei Wu, MD. PhD, The First Affiliated Hospital Of Soochow University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 29, 2021
Primary Completion (Estimated)
December 30, 2025
Study Completion (Estimated)
June 30, 2026
Study Registration Dates
First Submitted
January 16, 2022
First Submitted That Met QC Criteria
February 6, 2022
First Posted (Actual)
February 15, 2022
Study Record Updates
Last Update Posted (Actual)
May 14, 2024
Last Update Submitted That Met QC Criteria
May 13, 2024
Last Verified
May 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HYML-122-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relapsed or Refractory Acute Myeloid Leukemia (AML)
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Not yet recruitingTreatment-naive or Relapsed or Refractory Acute Myeloid Leukemia (AML)China
-
AstraZenecaTerminatedRelapsed or Refractory Acute Myeloid Leukemia (AML)United States
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.TerminatedRelapsed or Refractory Acute Myeloid Leukemia (AML)China
-
AvenCell Europe GmbHGCP-Service International Ltd. & Co. KGTerminatedAcute Myeloid Leukemia | Relapsed AML | Refractory AMLGermany
-
Elucida OncologyTherapeutic Advances in Childhood Leukemia and Lymphoma (TACL)WithdrawnAcute Myeloid Leukemia | AML, Childhood | Relapsed Pediatric AML | Refractory Pediatric AML
-
Tarapeutics Science Inc.RecruitingRelapsed or Refractory Acute Myeloid Leukemia (AML)China
-
German Cancer Research CenterUniversity Hospital Heidelberg; University Hospital DresdenNot yet recruitingRelapsed/Refractory Acute Myeloid Leukemia (AML)Germany
-
New Epsilon Innovation LimitedActive, not recruitingAdvanced Solid Tumor | Relapsed AML | Refractory AMLHong Kong
-
French Innovative Leukemia OrganisationAcute Leukemia French AssociationRecruitingAML, Adult | Relapsed Adult AML | Refractory AML | FLT3-TKD Mutation | FLT3-ITDFrance
-
Arog Pharmaceuticals, Inc.CompletedRelapsed/Refractory Acute Myeloid Leukemia (AML)United States
Clinical Trials on HYML-122
-
Tarapeutics Science Inc.RecruitingRelapsed or Refractory Acute Myeloid Leukemia (AML)China
-
TaiwanJ Pharmaceuticals Co., LtdNot yet recruitingNonalcoholic Steatohepatitis (NASH) With Fibrosis
-
Santen Inc.CompletedAge-Related Macular DegenerationUnited States
-
CelgeneCompletedClinical Pharmacology, Healthy Male Volunteer StudyUnited States
-
TaiwanJ Pharmaceuticals Co., LtdTerminated
-
CelgeneCompleted
-
CelgeneCompletedRenal InsufficiencyUnited States
-
Metastatix, Inc.SuspendedSolid TumorsUnited States
-
Bausch Health Americas, Inc.CompletedPlaque PsoriasisUnited States